Affiliation:
1. Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy
2. Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy
3. Cardiology Unit, “Santa Maria della Misericordia” Hospital, 61029 Urbino, Italy
Abstract
Background: During the physiological cardiac cycle, the helix orientation of the muscle fibres induces the rotation of the apex relative to the base of the left ventricular (LV). In heart failure, LV torsion is impaired, and rotation at basal and apical levels occurs in the same direction, a phenomenon called rigid body rotation (RBR). We aimed to evaluate whether the RBR pattern and GLS together could improve the diagnosis of cardiotoxicity in patients treated with anthracyclines and/or anti-HER2. Methods: With an observational, retrospective study involving 175 patients (mean age 55 ± 12 years, 94% females), we evaluated the development of cancer therapeutic–related cardiac dysfunction (CTRCD) defined according to ESC guidelines. We characterised LV dysfunction by echocardiographic standard and speckle-tracking (GLS and RBR pattern) measurements. Patients with a previous diagnosis of structural heart disease or atrial fibrillation were excluded. Results: At the time of enrolment, the chemotherapy regimen included trastuzumab (96%), pertuzumab (21%), and anthracyclines (13%). Twenty-two patients (12.5%) developed cardiotoxicity, and thirteen patients developed an RBR within 6 months of follow-up. In all cases, the RBR pattern was associated with cardiotoxicity (p < 0.001), reporting an optimal specificity but poor sensitivity at three and six months. However, the addition of the RBR pattern to the global longitudinal strain (GLS) ≥ −16% increased the odds ratio (OR) from 25.6 to 32.6 at three months and from 32.5 to 49.6 at six months rather than GLS alone. Conclusions: The RBR pattern improves the diagnostic accuracy of GLS for the detection of cardiotoxicity secondary to anthracyclines and anti-HER2-based treatments.
Funder
Marche Polytechnic University
Susan G. Komen Italia
Reference23 articles.
1. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations;Curigliano;Ann. Oncol.,2020
2. ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur. Heart J., 43, 4229–4361.
3. Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management;Truong;Can. J. Cardiol.,2014
4. Cancer Therapy–Related Cardiac Dysfunction and Heart Failure;Bloom;Circ. Heart Fail.,2016
5. Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer;Khouri;Circulation,2012